Showing results (71-80 of 118) with videos related to
Sort By:
Pageof 12
Nature Communications|August 6, 2016
Endothelial PDGF-CC regulates angiogenesis-dependent thermogenesis in beige fatTakahiro Seki, Kayoko Hosaka, Sharon Lim, et al.Eclinicalmedicine|August 20, 2025
Trastuzumab deruxtecan in patients from China with previously treated human epidermal growth factor receptor 2-positive locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): results from a single-arm, multicenter, phase 2 trialZhi Peng, Ping Chen, Jin Lu, et al.Cancer|June 7, 2023
Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancerQing Zhou, Jun Zhao, Jianhua Chang, et al.Endocrine-Related Cancer|January 23, 2024
Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patientsXiangqian Zheng, Meiyu Fang, Yun Fan, et al.Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|September 7, 2025
Development and validation of a machine learning model for predicting immune checkpoint inhibitor efficacy in advanced gastric cancer using dynamic changes in peripheral blood clinlabomics data: a retrospective multicenter cohort studyShulun Nie, Shuyi Song, Qian Xu, et al.The Lancet. Respiratory Medicine|June 23, 2025
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trialYuankai Shi, Lin Wu, Yinghua Ji, et al.Frontiers in Immunology|November 9, 2023
The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trialQian Qiao, Chun Han, Sisi Ye, et al.Cancer Chemotherapy and Pharmacology|October 8, 2025
A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation resultsJayesh Desai, Sanjeev Deva, Bo Gao, et al.Journal for Immunotherapy of Cancer|February 22, 2023
SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancerJun Zhao, Xinmin Yu, Dingzhi Huang, et al.JAMA|February 24, 2025
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical TrialXiaotian Zhang, Jufeng Wang, Gang Wang, et al.Pageof 12